

Attorney Docket No.: FHW-051US  
Group Art Unit: 1645

U.S.S.N. 09/445,289

- 2 -

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

127. The method of claim 126, wherein the polypeptide is recombinant.

128. The method of claim 126 or claim 127, wherein said polypeptide is used in therapy, diagnosis or prophylaxis of a microbial infection.

129. The method of claim 128, wherein the therapy is immunotherapy.

130. The method of claim 126 or claim 127, wherein said polypeptide is in a pharmaceutically acceptable carrier suitable for local or systemic administration.

131. The method of claim 126 or 127, wherein the polypeptide is in unit dosage form.

132. A pharmaceutical composition for resuscitating dormant, moribund or latent bacterial cells comprising,

a therapeutically effective amount of a polypeptide selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2, and

Attorney Docket No.: FHW-051US  
Group Art Unit: 1645

U.S.S.N. 09/445,289

- 3 -

a pharmaceutically acceptable carrier therefor.

133. The composition of claim 132, wherein the composition is a vaccine.

134. The composition of claim 133, wherein the vaccine is a live vaccine comprising an attenuated microbe.

135. A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with an antibody or functional fragment thereof that binds a polypeptide selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

136. The method of claim 135, wherein the antibody is suitable for use in therapy, diagnosis, or prophylaxis of a microbial infection.

137. The method of claim 136, wherein the therapy is an immunotherapy.

138. The method of claim 136, wherein the antibody is in a pharmaceutically acceptable carrier suitable for local or systemic administration.

139. The method of claim 136, wherein the antibody is in unit dosage form.

140. A method for resuscitating dormant, moribund or latent bacterial cells comprising, introducing into cells an isolated nucleic acid encoding a polypeptide comprising a sequence selected from the group consisting of:

Attorney Docket No.: FHW-051US  
Group Art Unit: 1645

U.S.S.N. 09/445,289

- 4 -

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

141. The method of claim 140, wherein said nucleic acid is in a pharmaceutically acceptable carrier.

142. A method for resuscitating dormant, moribund or latent bacterial cells comprising, introducing into cells an expression vector comprising a nucleic acid encoding a polypeptide comprising a sequence selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

143. The method of claim 142, wherein the vector is in a pharmaceutically acceptable carrier.

144. A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with a cell strain expressing a nucleic acid encoding a polypeptide comprising a sequence selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

Attorney Docket No.: FHW-051US  
Group Art Unit: 1645

U.S.S.N. 09/445,289

- 5 -

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

145. A diagnostic kit for detecting dormant, moribund or latent bacterial cells comprising a polypeptide having a sequence selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2, and instructions for use in diagnosis to detect dormant, moribund or latent bacterial cells.

146. A culture medium for resuscitating dormant, moribund or latent bacterial cells comprising a polypeptide having a sequence selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

Attorney Docket No.: FHW-051US  
Group Art Unit: 1645

U.S.S.N. 09/445,289

- 6 -

147. A transport medium for resuscitating dormant, moribund or latent bacterial cells comprising a polypeptide having a sequence selected from the group consisting of:

i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2

ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;

iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and

v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

---